Cargando…

The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging

Non-small cell lung cancer (NSCLC) metastasis commonly occurs in bone, which often results in pathological fractures. Sustained phosphoinositide-3-kinase (PI3K) signalling promotes the growth of PI3K-dependent NSCLC and elevates osteoclastogenic potential. The present study investigated the effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shengfei, Niu, Xiaomin, Bao, Xiao, Wang, Qin, Zhang, Jianping, Lu, Shun, Wang, Yongjun, Xu, Ling, Wang, Mingwei, Zhang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448067/ https://www.ncbi.nlm.nih.gov/pubmed/30896825 http://dx.doi.org/10.3892/or.2019.7080

Ejemplares similares

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

A phase II study of buparlisib in relapsed or refractory thymomas
por: Abu Zaid, Mohammad I., et al.
Publicado: (2022)

The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies
por: Luo, Qian, et al.
Publicado: (2019)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
por: Piha-Paul, Sarina A., et al.
Publicado: (2019)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
por: McGowan, Daniel R., et al.
Publicado: (2019)

Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis
por: Dai, Rongchen, et al.
Publicado: (2022)

CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages
por: Jiang, Pengling, et al.
Publicado: (2019)

Multimodality imaging findings of cardiac neuroendocrine tumour metastasis
por: Rafiee, Moezedin Javad, et al.
Publicado: (2023)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
por: Kim, Hye Ryun, et al.
Publicado: (2020)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
por: Nixon, Mellissa J., et al.
Publicado: (2019)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

The Osteoclast in Bone Metastasis: Player and Target
por: Maurizi, Antonio, et al.
Publicado: (2018)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis
por: Niu, Qing, et al.
Publicado: (2022)

Emotional mimicry signals pain empathy as evidenced by facial electromyography
por: Sun, Ya-Bin, et al.
Publicado: (2015)

The harpooning mechanism as evidenced in the oxidation reaction of the Al atom
por: Li, Fangfang, et al.
Publicado: (2017)

Updates on the Clinical Evidenced Herb-Warfarin Interactions
por: Ge, Beikang, et al.
Publicado: (2014)

Mycobacterium tuberculosis infection increases the number of osteoclasts and inhibits osteoclast apoptosis by regulating TNF-α-mediated osteoclast autophagy
por: Liu, Wei, et al.
Publicado: (2020)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

The role of osteoclasts in breast cancer bone metastasis
por: Le Pape, François, et al.
Publicado: (2016)

PI3K activation increases SDF-1 production and number of osteoclast precursors, and enhances SDF-1-mediated osteoclast precursor migration
por: Adapala, Naga Suresh, et al.
Publicado: (2019)

Crassisporus gen. nov. (Polyporaceae, Basidiomycota) evidenced by morphological characters and phylogenetic analyses with descriptions of four new species
por: Ji, Xing, et al.
Publicado: (2019)

Evidenced-Based Claims About Evidence
por: Howard, David H.
Publicado: (2017)

Professional Sentiment as Evidenced by the Medical Press
Publicado: (1885)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Two cases of breast carcinoma with osteoclastic giant cells: Are the osteoclastic giant cells pro-tumoural differentiation of macrophages?
por: Shishido-Hara, Yukiko, et al.
Publicado: (2010)

ID2 Inhibits Bladder Cancer Progression and Metastasis via PI3K/AKT Signaling Pathway
por: Mao, Weipu, et al.
Publicado: (2021)

Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer
por: Liu, Jin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fmolc4cari14redj29516irrod